Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Tocilizumab (Primary)
- Indications Polymyalgia rheumatica
- Focus Therapeutic Use
- Acronyms SEMAPHORE
- 15 Feb 2017 Planned End Date changed from 1 Dec 2020 to 1 Jan 2021.
- 15 Feb 2017 Planned primary completion date changed from 1 Dec 2019 to 15 Sep 2020.
- 15 Feb 2017 Status changed from not yet recruiting to recruiting.